Estimation of radiation dosimetry for 68Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancer

Mark Green, Jacob A. Eitel, James Fletcher, Carla J. Mathias, Mark A. Tann, Wendy Territo, Heather Polson, Gary Hutchins, Thomas Gardner, Michael Koch

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction This study was performed to estimate the human radiation dosimetry for [68Ga]Ga-HBED-CC (PSMA-11) (68Ga PSMA-11). Methods Under an RDRC-approved research protocol, we evaluated the biodistribution and pharmacokinetics of 68Ga PSMA-11 with serial PET imaging following intravenous administration to nine prostate cancer patients in whom clinical [11C]acetate PET/CT exams had been independently performed under Expanded Access IND 118,204. List-mode imaging was performed over the initial 0–10 min post-injection with the pelvis in the field-of-view. Whole-body images were acquired, pelvis-to-head, at 15, 60, and 90-min post-injection. Additional images of the pelvis were acquired at 40-min and 115-min, and voided urine collected from each subject at 48-min and 120-min post-injection. Radiation dosimetry estimates were calculated from these data using the OLINDA software package. Results Renal uptake was high and relatively invariant, ranging from 11% to 14% of the injected dose between 15 and 90-min post-injection. Radioactivity collected in the voided urine accounted for 14% of the injected dose over a period of 120-min. Lymph nodes and skeletal metastases suspicious for prostate cancer recurrence were detected in a greater number of patients using 68Ga PSMA-11 than using 11C-acetate. Conclusion Kidneys are the critical organ following 68Ga PSMA-11 administration, receiving an estimated dose of 0.413 mGy/MBq. Advances in knowledge and implications for patient care This study confirms that the kidneys will be the critical organ following intravenous administration of 68Ga PSMA-11, and provided data consistent with the expectation that 68Ga PSMA-11 will be superior to [11C]acetate for defining sites of recurrence in prostate cancer patients presenting with biochemical relapse.

Original languageEnglish (US)
Pages (from-to)32-35
Number of pages4
JournalNuclear Medicine and Biology
Volume46
DOIs
StatePublished - Mar 1 2017

Fingerprint

Radiometry
Prostatic Neoplasms
Recurrence
Pelvis
Injections
Kidney
Intravenous Administration
Urine
Body Image
Radioactivity
N,N'-bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine N,N'-diacetic acid
Patient Care
Software
Pharmacokinetics
Lymph Nodes
Head
Neoplasm Metastasis
Research
carbon-11 acetate

Keywords

  • Ga-DKFZ-PSMA-11
  • Ga-HBED-CC (PSMA-11)
  • Dosimetry
  • Glu-NH-CO-NH-Lys-(Ahx)-[Ga(HBED-CC)]
  • Prostate cancer recurrence
  • PSMA-targeted PET/CT

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Estimation of radiation dosimetry for 68Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancer. / Green, Mark; Eitel, Jacob A.; Fletcher, James; Mathias, Carla J.; Tann, Mark A.; Territo, Wendy; Polson, Heather; Hutchins, Gary; Gardner, Thomas; Koch, Michael.

In: Nuclear Medicine and Biology, Vol. 46, 01.03.2017, p. 32-35.

Research output: Contribution to journalArticle

@article{4666e37f5091486fa7b73b4ce193b6e6,
title = "Estimation of radiation dosimetry for 68Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancer",
abstract = "Introduction This study was performed to estimate the human radiation dosimetry for [68Ga]Ga-HBED-CC (PSMA-11) (68Ga PSMA-11). Methods Under an RDRC-approved research protocol, we evaluated the biodistribution and pharmacokinetics of 68Ga PSMA-11 with serial PET imaging following intravenous administration to nine prostate cancer patients in whom clinical [11C]acetate PET/CT exams had been independently performed under Expanded Access IND 118,204. List-mode imaging was performed over the initial 0–10 min post-injection with the pelvis in the field-of-view. Whole-body images were acquired, pelvis-to-head, at 15, 60, and 90-min post-injection. Additional images of the pelvis were acquired at 40-min and 115-min, and voided urine collected from each subject at 48-min and 120-min post-injection. Radiation dosimetry estimates were calculated from these data using the OLINDA software package. Results Renal uptake was high and relatively invariant, ranging from 11{\%} to 14{\%} of the injected dose between 15 and 90-min post-injection. Radioactivity collected in the voided urine accounted for 14{\%} of the injected dose over a period of 120-min. Lymph nodes and skeletal metastases suspicious for prostate cancer recurrence were detected in a greater number of patients using 68Ga PSMA-11 than using 11C-acetate. Conclusion Kidneys are the critical organ following 68Ga PSMA-11 administration, receiving an estimated dose of 0.413 mGy/MBq. Advances in knowledge and implications for patient care This study confirms that the kidneys will be the critical organ following intravenous administration of 68Ga PSMA-11, and provided data consistent with the expectation that 68Ga PSMA-11 will be superior to [11C]acetate for defining sites of recurrence in prostate cancer patients presenting with biochemical relapse.",
keywords = "Ga-DKFZ-PSMA-11, Ga-HBED-CC (PSMA-11), Dosimetry, Glu-NH-CO-NH-Lys-(Ahx)-[Ga(HBED-CC)], Prostate cancer recurrence, PSMA-targeted PET/CT",
author = "Mark Green and Eitel, {Jacob A.} and James Fletcher and Mathias, {Carla J.} and Tann, {Mark A.} and Wendy Territo and Heather Polson and Gary Hutchins and Thomas Gardner and Michael Koch",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.nucmedbio.2016.11.002",
language = "English (US)",
volume = "46",
pages = "32--35",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Estimation of radiation dosimetry for 68Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancer

AU - Green, Mark

AU - Eitel, Jacob A.

AU - Fletcher, James

AU - Mathias, Carla J.

AU - Tann, Mark A.

AU - Territo, Wendy

AU - Polson, Heather

AU - Hutchins, Gary

AU - Gardner, Thomas

AU - Koch, Michael

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Introduction This study was performed to estimate the human radiation dosimetry for [68Ga]Ga-HBED-CC (PSMA-11) (68Ga PSMA-11). Methods Under an RDRC-approved research protocol, we evaluated the biodistribution and pharmacokinetics of 68Ga PSMA-11 with serial PET imaging following intravenous administration to nine prostate cancer patients in whom clinical [11C]acetate PET/CT exams had been independently performed under Expanded Access IND 118,204. List-mode imaging was performed over the initial 0–10 min post-injection with the pelvis in the field-of-view. Whole-body images were acquired, pelvis-to-head, at 15, 60, and 90-min post-injection. Additional images of the pelvis were acquired at 40-min and 115-min, and voided urine collected from each subject at 48-min and 120-min post-injection. Radiation dosimetry estimates were calculated from these data using the OLINDA software package. Results Renal uptake was high and relatively invariant, ranging from 11% to 14% of the injected dose between 15 and 90-min post-injection. Radioactivity collected in the voided urine accounted for 14% of the injected dose over a period of 120-min. Lymph nodes and skeletal metastases suspicious for prostate cancer recurrence were detected in a greater number of patients using 68Ga PSMA-11 than using 11C-acetate. Conclusion Kidneys are the critical organ following 68Ga PSMA-11 administration, receiving an estimated dose of 0.413 mGy/MBq. Advances in knowledge and implications for patient care This study confirms that the kidneys will be the critical organ following intravenous administration of 68Ga PSMA-11, and provided data consistent with the expectation that 68Ga PSMA-11 will be superior to [11C]acetate for defining sites of recurrence in prostate cancer patients presenting with biochemical relapse.

AB - Introduction This study was performed to estimate the human radiation dosimetry for [68Ga]Ga-HBED-CC (PSMA-11) (68Ga PSMA-11). Methods Under an RDRC-approved research protocol, we evaluated the biodistribution and pharmacokinetics of 68Ga PSMA-11 with serial PET imaging following intravenous administration to nine prostate cancer patients in whom clinical [11C]acetate PET/CT exams had been independently performed under Expanded Access IND 118,204. List-mode imaging was performed over the initial 0–10 min post-injection with the pelvis in the field-of-view. Whole-body images were acquired, pelvis-to-head, at 15, 60, and 90-min post-injection. Additional images of the pelvis were acquired at 40-min and 115-min, and voided urine collected from each subject at 48-min and 120-min post-injection. Radiation dosimetry estimates were calculated from these data using the OLINDA software package. Results Renal uptake was high and relatively invariant, ranging from 11% to 14% of the injected dose between 15 and 90-min post-injection. Radioactivity collected in the voided urine accounted for 14% of the injected dose over a period of 120-min. Lymph nodes and skeletal metastases suspicious for prostate cancer recurrence were detected in a greater number of patients using 68Ga PSMA-11 than using 11C-acetate. Conclusion Kidneys are the critical organ following 68Ga PSMA-11 administration, receiving an estimated dose of 0.413 mGy/MBq. Advances in knowledge and implications for patient care This study confirms that the kidneys will be the critical organ following intravenous administration of 68Ga PSMA-11, and provided data consistent with the expectation that 68Ga PSMA-11 will be superior to [11C]acetate for defining sites of recurrence in prostate cancer patients presenting with biochemical relapse.

KW - Ga-DKFZ-PSMA-11

KW - Ga-HBED-CC (PSMA-11)

KW - Dosimetry

KW - Glu-NH-CO-NH-Lys-(Ahx)-[Ga(HBED-CC)]

KW - Prostate cancer recurrence

KW - PSMA-targeted PET/CT

UR - http://www.scopus.com/inward/record.url?scp=85007294233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007294233&partnerID=8YFLogxK

U2 - 10.1016/j.nucmedbio.2016.11.002

DO - 10.1016/j.nucmedbio.2016.11.002

M3 - Article

VL - 46

SP - 32

EP - 35

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

ER -